Arterial Stiffness and Endothelial Function in Heart Failure
ConditionHeart Failure
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorCoventry University
About this trial
Heart Failure (HF) is a global condition affecting at least 26 million people worldwide. Despite advances in treatment, HF patients continue to experience poor health outcomes. This study aims to improve understanding of the role of blood vessels in people with heart failure.
The study will assess how arterial stiffness (how stiff blood vessels are) and endothelial function (how well the lining of blood vessels functions) change over time and respond to treatments received as part of routine clinical care. Blood vessel function and heart performance will be assessed at three time points:
* At baseline (when Patients are first diagnosed with heart failure). * After completing 4 ± 2 weeks of heart-failure medicines prescribed to patients as part of their routine clinical care. * After completion of cardiac rehabilitation program as a part of their routine clinical care.
All assessments are non-invasive.
Eligibility criteria
Qualifiers
Male and female ≥ 18 years old.
Have a confirmed de-novo diagnosis of Heart failure with preserved ejection fraction or Heart failure with reserved ejection fraction. Common HF phenotypes (e.g., hypertension, diabetes, obesity) will be recorded as part of routine baseline data but will not influence recruitment or sampling. .
Have stable Heart failure in the opinion of the investigator.
Have ability, in the opinion of the investigator, to participate in study activities.
Disqualifiers
• Inability to provide verbal informed consent.
Presenting with severe symptoms; major co-morbidity or other alternative diagnoses (e.g., malignancy, severe respiratory disease, severe mental health problem/s).
Recent acute coronary syndrome (within 60 days).
Severe physical disability preventing independence.
Trial design
Treatments tested in this trial
- Study Assessment
Treatment groups
50 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov